BTK and Waldenstrom macroglobulinemia: Orelabrutinib, a second-generation BTK inhibitor, has shown potential clinical efficacy in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and relapsed or refractory Waldenström macroglobulinemia (4–6).